Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Hypopharyngeal cancer
Stage/Subtype:  stage III hypopharyngeal cancer
Country:  U.S.A.
Trial Type:  Treatment
Results 1-25 of 55 for your search:
Start Over
Radiation Therapy with Cisplatin, Docetaxel, or Cetuximab and Docetaxel after Surgery in Treating Patients with High-Risk Stage III-IV Squamous Cell Head and Neck Cancer
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: RTOG 1216, NCI-2013-00500, NCT01810913
LUX-Head&Neck 2: A Phase III Trial of Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapy
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 1200.131, NCI-2012-02044, 2011-000392-14, NCT01345669
Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141)
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CA209-141, NCI-2014-01268, 2013-003622-86, NCT02105636
Cetuximab, EGFR Antisense DNA, and Radiation Therapy in Treating Patients With Stage III-IV Squamous Cell Cancer of the Head and Neck
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: UPCI 06-121, NCI-2013-00329, NCT00903461
Combination Chemotherapy with or without Veliparib in Treating Patients with Stage IV Head and Neck Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: A091101, NCI-2012-02009, NCT01711541
Palbociclib and Cetuximab in Treating Patients with Squamous Cell Carcinoma of the Head and Neck
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 201404139, NCI-2014-01079, 14-X031, NCT02101034
A Phase 1b/2 Safety and Tolerability of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: D4981C00001, NCI-2014-01959, NCT02205333
A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CDX1127-02, NCI-2015-00273, NCT02335918
Cetuximab Followed By Surgery and Chemoradiation Therapy in Treating Patients With Previously Untreated Stage III-IVA Head and Neck Squamous Cell Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: UPCI 08-013, NCI-2011-02479, NCT01218048
Cetuximab and Radiation Therapy in Treating Patients with Locally Advanced Head and Neck Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 70 and over
Trial IDs: UMCC 2009.009, NCI-2011-03619, HUM00027253, NCT01250522, NCT00904345
Docetaxel, Cisplatin, and Cetuximab in Treating Patients With Metastatic or Relapsed Head and Neck Cancer
Phase: Phase II
Type: Treatment
Age: 16 and over
Trial IDs: ENT0033, NCI-2011-03271, 22329, SU-08222011-8290, NCT01437449
TRYHARD: Radiation Therapy Plus Cisplatin With or Without Lapatinib in Treating Patients With Head and Neck Cancer.
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: RF-3501, NCI-2014-01403, LAP116153, NCT01711658
Tadalafil in Treating Patients With Head and Neck Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 21 and over
Trial IDs: J1247, NCI-2012-02047, CIR00001158, NA_00073880, NCT01697800
Cisplatin and Radiation Therapy with or without Dose Boost in Treating Patients with Stage III-IV Head and Neck Cancer
Phase: Phase II
Type: Treatment
Age: Over 18
Trial IDs: UMCC 2013.062, NCI-2013-01978, 2013.062, HUM00074305, NCT02031250
Stereotactic Radiosurgery and Cetuximab with or without Docetaxel in Treating Patients with Recurrent Head and Neck Cancer Previously Treated with Radiation Therapy
Phase: Phase II
Type: Treatment
Age: Over 18
Trial IDs: 11-112, NCI-2014-01954, REN13090047, UPCI 11-112, NCT02057107
Radiation Therapy With Cisplatin or Docetaxel and Cetuximab in Treating Patients With Stage III-IVB Head and Neck Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: UPCI 13-056, NCI-2014-01116, 13-056, PRO13080400, NCT02128906
Pembrolizumab in Treating Patients with Locoregionally Advanced Head and Neck Cancer That Can Be Removed by Surgery
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 201412118, NCI-2014-02626, 14-x330, NCT02296684
Trial of pIL-12 Electroporation in Squamous Cell Carcinoma of the Head and Neck (IL12HNSCC)
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: OMS-I130, NCI-2015-00840, NCT02345330
Vaccinia Virus in Treating Patients With Solid Tumors
Phase: Phase I
Type: Treatment
Age: Over 18
Trial IDs: 06-041, NCI-2011-02461, NCT00574977
Start Over